Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
126,707 studies indexed
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03762733 | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | terminated | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 28, 2026 |
| clinicaltrials |
| NCT03834493 | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | terminated | Phase 3 | 1,244 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT03865992 | Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease | active not recruiting | N/A | 42 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03976323 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | completed | Phase 3 | 1,003 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04065009 | The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer(IPLA-OVCA) | active not recruiting | Phase 3 | 220 | Karolinska InstitutetOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04071223 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | active not recruiting | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04086485 | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | recruiting | Phase 1 / Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma(CARTITUDE-4) | active not recruiting | Phase 3 | 419 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT04235764 | En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device | recruiting | — | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04235777 | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04257500 | Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS(RING-PCOS) | completed | Phase 4 | 22 | Andrea Roe, MD, MPHOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | recruiting | Phase 3 | 247 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | terminated | Phase 2 | 52 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | recruiting | Phase 3 | 416 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 32 | Jasper Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04442425 | Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain | completed | — | 83 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04449549 | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04487080 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA) | active not recruiting | Phase 3 | 1,074 | Janssen Research & Development, LLCINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)(AMPLITUDE) | active not recruiting | Phase 3 | 696 | Janssen Research & Development, LLCINDUSTRY | 33 | Sep 28, 2026 | clinicaltrials |
| NCT04541030 | Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies | active not recruiting | — | 241 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04573231 | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04577755 | Pomalidomide Treatment in Patients With Kaposi Sarcoma | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04644770 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | active not recruiting | Phase 1 | 144 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04645160 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04660344 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy(IMvigor011) | active not recruiting | Phase 3 | 761 | Hoffmann-La RocheINDUSTRY | 23 | Sep 28, 2026 | clinicaltrials |
| NCT04662580 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer(ARX517) | active not recruiting | Phase 1 | 183 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04706663 | Precision-Based Genomics in Prostate Cancer | recruiting | — | 2,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04711252 | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease(SERENA-4) | active not recruiting | Phase 3 | 1,371 | AstraZenecaINDUSTRY | 27 | Sep 28, 2026 | clinicaltrials |
| NCT04722146 | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MajesTEC-2) | active not recruiting | Phase 1 | 140 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT04789694 | Prehabilitation in Gynaecological Cancer Patients(PHOCUS) | recruiting | Phase 3 | 64 | Charles University, Czech RepublicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT04868149 | Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS | completed | N/A | 20 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04883957 | Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies | completed | Phase 1 | 64 | BeiGeneINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04923542 | SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05015426 | Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT | active not recruiting | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05025488 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 7 | Marina KremyanskayaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | withdrawn | Phase 1 | 0 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MonumenTAL-2) | active not recruiting | Phase 1 | 166 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma(MAHOGANY) | active not recruiting | Phase 3 | 799 | BeOne MedicinesINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT05103358 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | completed | Phase 2 | 128 | Aadi Bioscience, Inc.INDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05196087 | Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)(NIP IT!) | recruiting | — | 800 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 2 days agoSource updated unknownsource: clinicaltrials